Expression of fragile X in human-mouse somatic cell hybrids

Fragile X expression was studied in human-mouse cell hybrids prepared from lymphocytes and fibroblasts obtained from a mentally retarded male. The patient showed a fragile X in 29-35.5% of his lymphocytes in medium 199 (M199) and in M199 plus fluorodeoxyuridine (FdU). One lymphocyte hybrid clone showed no expression in M199 and low expression in M199 + FdU. The other lymphocyte hybrid clone showed significantly increased expression in both media, comparable to levels in the parental cells. Fibroblast cultures from the patient showed no fragile X expression in M199 and 17% expression in M199 + FdU. Fragile X expression was also found in fibroblast hybrid clones in M199 and was significantly enhanced by the addition of FdU. Fragile X expression in one clone was consistently lower than in the other two clones and in the parental fibroblasts. Our results indicate that the level of fragile X expression varies in the hybrid clones, since frequencies similar to those of parental cells and suppressed frequencies were found. The presence or absence of a specific human chromosome did not correlate with the level of fragile X expression.     

Inhibition of brain hexokinase by a multisubstrate analog results from binding to a discrete regulatory site

P1-(adenosine-5')-P3-(glucose-6)-triphosphate (Ap3glucose) is a linear uncompetitive inhibitor vs glucose and a linear mixed inhibitor vs ATP of brain hexokinase, an inhibition pattern inconsistent with binding of Ap3glucose to the catalytic site when either the rapid equilibrium random or ordered sequential mechanism, which have been proposed for this enzyme, is considered. It is concluded that inhibition results from binding to a discrete regulatory site. The apparent ability of the regulatory site to accommodate both hexose and nucleotide moieties is consistent with suggestions by previous investigators that the regulatory site on mammalian hexokinases may have evolved from what was originally a catalytic site.